Published on Journal of Alzheimer's Disease (https://www.j-alz.com)

Home > Safety, tolerability, pharmacokinetics, and pharmacodynamics of the positive modulator of HGF/MET, fosgonimeton, in healthy volunteers and subjects with Alzheimer’s disease: randomized, placebo-controlled, double-blind, phase I clinical trial

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the positive modulator of HGF/MET, fosgonimeton, in healthy volunteers and subjects with Alzheimer’s disease: randomized, placebo-controlled, double-blind, phase I clinical trial

Manuscript Number: 

21-5511R1

Author(s): 
Kevin Church, Philippe Danjou, Suzanne B. Hendrix, Xue Hua, Philippe L’Hostis, Hans J. Moebius, Geoffrey Viardot, William Walker
Source URL: https://www.j-alz.com/manuscript-disclosures/21-5511r1